BusinessUpdated 16 min ago
FDA investigates tumour risk linked to Novartis’ Zolgensma gene therapy
The investigation follows disclosures of tumour cases in children, prompting fresh scrutiny of the safety of the one-time gene therapy
Continue reading on BusinessLine
Read full story Hello Headlines links you to the original publisher for the full story.



